Advertisement

Topics

I-Therapeutix, Inc. Company Profile

23:27 EDT 20th September 2017 | BioPortfolio


News Articles [88 Associated News Articles listed on BioPortfolio]

Ocular Therapeutix tumbles on further FDA delay for Dextenza

Ocular Therapeutix says it received a Complete Response Letter (CRL) from the US Food and Drug Administration…

Ocular Therapeutix appoints Michael Goldstein as CMO

US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael…

Ocular Therapeutix Receives Complete Response Letter from FDA for Dextenza NDA

BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 11, 2017-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative thera...

Ocular Therapeutix reported dextenza phase III data

Ocular Therapeutix, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, presented ocular pain da...

FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues

Ocular Therapeutix failed for a second time to secure approval of its eye drug Dextenza. On Tuesday, the FDA rejected the drug.

Manufacturing Deficiencies Delay Ocular Pain Therapy Progress

NewsOcular Therapeutix receives complete response letter from FDA for Dextenza NDA. The company believes that approval will come once the open manufacturing items are resolved.

STAT Plus: Ocular Therapeutix FDA approval imperiled by drug contamination concerns

An experimental eye drug from Ocular Therapeutix, already rejected once by the FDA, could this month be turned away a second time because of product contamination, including aluminum, found by…

VIDEO: Ocular Therapeutix makes progress on drug candidates

BALTIMORE — Jonathan Talamo, MD, chief medical officer of Ocular Therapeutix, discusses the company’s pipeline development products, including its clinical development program for Dextenza (dexame...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Ocular Therapeutix, Inc. 

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of t...

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietar...

Ora, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its p...

I-Therapeutix, Inc.

More Information about "I-Therapeutix, Inc." on BioPortfolio

We have published hundreds of I-Therapeutix, Inc. news stories on BioPortfolio along with dozens of I-Therapeutix, Inc. Clinical Trials and PubMed Articles about I-Therapeutix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of I-Therapeutix, Inc. Companies in our database. You can also find out about relevant I-Therapeutix, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record